Introduction
There is accumulating evidence that many antitumor therapies function by inducing apoptosis of tumor cells. [1] [2] [3] [4] Conversely, a major mode of resistance to antitumor therapy is insensitivity to apoptosis induction. [2] [3] [4] Apoptosis, which is a genetically regulated mechanism of cell death, is initiated through two major cell-intrinsic pathways: the mitochondrial pathway and membrane pathway. [5] [6] [7] A variety of genes are involved in these two pathways, some of which have a proapoptotic function, while others have an antiapoptotic function. The relative balance between these competing activities determines cell fate, to die or not to die. 5, 8 Therefore, enforced, selective overexpression of the proapoptotic genes involved in these two pathways in malignant cells effectively changes this balance, leading to apoptosis.
As potent apoptosis promoters, the Bax and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) proteins are two well-characterized molecules that elicit apoptosis through one of the two distinct apop- totic pathways. In particular, the Bax protein, which is a member of the Bcl-2 family, induces the release of cytochrome-c from mitochondria, which activates caspase-9, -3, and -7 and leads to apoptosis. 9, 10 The Bcl-2 protein, on the other hand, inhibits apoptosis by blocking the release of cytochrome-c from mitochondria. 11, 12 Thus, the Bcl-2/Bax ratio has been reported to be the critical determinant of induction or inhibition of apoptosis. 13 In contrast, the TRAIL protein, which is a member of the TNF family, triggers apoptosis by interacting with death receptors on the cell surface, 14, 15 which in turn activates caspase-8 through the Fas-associated death domain, leading to apoptosis. However, the antagonistic decoy receptors DcR1, 16, 17 DcR2, 18 and osteoprotegerin, 19 are believed to protect normal cells from the cytotoxic effects of TRAIL by competing with DR4 and DR5 for TRAIL binding.
We and others recently showed that direct transferral of the human Bax gene to cancer cells induces apoptosis and suppresses tumor growth in both p53-sensitive and p53-resistant cancer models. [20] [21] [22] [23] We and others also showed that direct transferral of the TRAIL gene into cancer cells can induce apoptosis and apoptotic bystander effects in malignant cells and suppress tumor growth in vivo. 24, 25 However, it is possible that certain malignant cells are relatively resistant to apoptosis induction one way or another.
We hypothesized that simultaneous activation of the mitochondrial and membrane apoptotic pathways would elicit a stronger apoptotic response than activation of only one of the pathways would, thereby providing a chance to kill malignant cells that are relatively refractory to apoptosis induction and reduce the vector doses required for treatment. To test this hypothesis, we evaluated the effects of adenoviral vectors expressing the GFP/TRAIL fusion gene or the Bax gene from the human telomerase reverse transcriptase (hTERT) promoter on three human cancer cell lines, including a refractory ovarian cancer line SKOV3 that is resistant to tumor necrosis factor and to several cytoxic drugs. Our results suggest that combined TRAIL and Bax gene therapy may indeed provide a chance to treat tumors that are relatively refractory to apoptosis induction.
Results

Transgene expression and apoptosis induction in cancer cells in vitro
The bicistronic adenoviral vector Ad/gTRAIL contains two expression cassettes. One cassette expresses the GFP/TRAIL fusion gene driven by the GAL4/TATA (GT) promoter, 26, 27 while the other expresses the GAL4/VP16 (GV16) fusion gene driven by the hTERT promoter. We previously showed that the GT promoter is silent in mammalian cells in the absence of GV16, but highly active in the presence of GV16. 27 Thus, expression of GAL4/GV16 driven by the hTERT promoter leads to activation of the GT promoter and expression of GFP/TRAIL fusion protein. We also previously showed that the adenoviral vector Ad/GT-Bax expresses the Bax gene when it is coadminstered with an adenoviral vector expressing the GV16 fusion protein. 21, 28 Therefore, it is believed that Ad/gTRAIL expresses the GFP/TRAIL fusion protein in hTERT-active cells. When coinfected with Ad/GT-Bax, Ad/gTRAIL also induces Bax gene expression in hTERTactive cells (Figure 1a) . Thus, unless otherwise stated, all the studies we undertook used Ad/gTRAIL for the expression of GFP/TRAIL; Ad/hTERT-GV16 plus Ad/GT-Bax for the expression of Bax; Ad/gTRAIL plus Ad/GT-Bax for the expression of both GFP/TRAIL and Bax; phosphate-buffered saline (PBS) and Ad/CMV-GFP plus Ad/GT-Bax were used as mock or vector controls. When two vectors were used, the total vector dose remained the same as that in the cells treated using the single vectors, the ratio of the two vectors was fixed at 1:1.
To determine the level of the transgene expression in cancer cells, cells were harvested 48-72 h after treatment, and the expression of GFP/TRAIL and Bax was analyzed using a fluorescence-activated cell sorting (FACS) and Western blot analysis, respectively. Cells treated by PBS or Ad/CMV-GFP + Ad/GT-Bax were used as mock or vector control. Cells were harvested 48-72 h after the treatment and the expression of GFP/TRAIL and Bax were analyzed by FACS and Western blot analysis, respectively. Treatment using Ad/gTRAIL alone resulted in GFP/TRAIL expression in 84% to 91% of the cancer cells tested (Figure 1b) . However, treatment using Ad/gTRAIL plus Ad/GT-Bax, resulted in GFP/TRAIL expression in 44% to 50% of the cells, reflecting an Ad/gTRAIL dose reduction in this group. GFP-positive cells were not detected when cells were treated using PBS or Ad/hTERT-GV16 plus Ad/GT-Bax. Additionally over-expression of the Bax protein was observed only in cells treated using Ad/gTRAIL plus Ad/GT-Bax or Ad/hTERT-GV16 plus Ad/GT-Bax (Figure 1c) . These results demonstrated that Ad/gTRAIL can express GFP/TRAIL fusion protein itself and induce the Bax gene expression when coadministered with Ad/GT-Bax.
We previously reported that direct transferral of the Bax gene or GFP/TRAIL fusion gene will induce apoptosis of cancer cells. 20, 24 To examine apoptosis induction by the GFP/TRAIL and Bax gene both separately and together, we tested the activation of caspase-8 and -3, and cleavage of poly (ADP-ribose) polymerase (PARP) using the same SKOV3ip samples that were used in testing for Bax expression (Figure 1c) . We detected activation of caspase-8 and -3 and cleavage of PARP in cells treated using vectors expressing the GFP/TRAIL and/or Bax genes but not in cells treated using PBS or control vectors (Figure 1c ). In addition, to quantify the level of apoptosis induction in cancer cells, we analyzed the DNA contents in the human ovarian cancer cell lines SKOV3ip and DOV13, and human lung cancer cell line H1299 using a FACS. We found that apoptosis was induced in SKOV3ip and H1299 cells when treated using GFP/TRAIL-or Baxexpressing vectors alone. Nevertheless, even though the same total vector dose was used in each cell line, apoptosis induction was more profound in cells treated using Ad/gTRAIL plus Ad/GT-Bax, which were the vectors expressing both GFP/TRAIL and Bax. This phenomenon was more prominent in SKOV3ip cells (Figure 2a ). However, in DOV13 cells, treatment using Ad/gTRAIL alone resulted in more apoptotic cells than did that using Ad/gTRAIL plus Ad/GT-Bax. This can be explained by the fact that the DOV13 cells were sensitive to the GFP/TRAIL-expressing vector, but highly resistant to the Bax-expressing vector. Thus, at the same total multiplicity of infection (MOI), the dose of the effective vector (Ad/gTRAIL) was doubled in the group that received Ad/gTRAIL alone when compared with the group that received Ad/gTRAIL plus Ad/GT-Bax. Nevertheless, treatment of DOV13 cells using Ad/gTRAIL plus Ad/GT-Bax effectively elicited apoptosis of DOV13 cells, while treatment using Ad/hTERT-GV16 plus Ad/GTBax did not.
To further document the cell-killing effects of the Bax and GFP/TRAIL genes both separately and together, we performed an XTT assay to measure cell viability within 1 week after treatment (Figure 2b ). The results of this assay were consistent with those of FACS analysis. Specifically, the DOV13 cells were highly sensitive to the GFP/TRAIL-expressing vector, but highly resistant to the Bax-expressing vector. The cell-killing effect of the combined therapy was therefore derived mainly from the expression of GFP/TRAIL. Furthermore, because the dose of effective vector (Ad/gTRAIL) in the combined group was only half of that in the group that received Ad/gTRAIL alone group, the cell-killing effect was reduced when compared with that in cells treated using Ad/gTRAIL alone. In contrast, in SKOV3ip and H1299 cells, treatment using the GFP/TRAIL-or Bax-expressing vectors alone elicited substantial cell death. Combined therapy using the GFP/TRAIL and Bax genes enhanced cell killing in these two cell lines. This enhancement of cell killing is more profound in SKOV3ip cells that are 
Figure 1 Transgene expression and apoptosis induction in cancer cells. (a) Diagram of induction of GFP/TRAIL and Bax. Ad/gTRAIL contains expression cassettes for the GAL4/VP16 (GV16) and GFP/TRAIL genes in replace of the E1 region (map unit 1.3~9.3) of human adenovirus type 5. Polyadenylation signal sequences from bovine growth hormone (BGH) and SV40 genes are used for these cassettes. GV16 expressed from hTERT promoter in
Transgene expression and apoptosis induction in normal human ovarian surface epithelial cells in vitro
To test whether treatment using Ad/gTRAIL plus Ad/GT-Bax resulted in transgene expression and apoptosis induction in normal cells, we performed FACS analysis and the XTT assay using normal human ovarian surface epithelial cells (NHOE) after treatment using various vectors. Also, Ad/PGK-GV16 plus Ad/GT-Bax was used as a positive control for apoptosis induction in those cells because we previously found that most normal cells are sensitive to Bax gene overexpression. 21, 28 FACS analysis showed that less than 5% of the cells were GFP-positive after treatment using Ad/gTRAIL at an MOI of 1000 vp/cells (Figure 3a) . In comparison, more than 80% of the cells were GFP-positive when treated using Ad/CMV-GFP plus Ad/GT-Bax at the same MOI (ratio, 1:1). This result suggests that normal ovarian epithelial cells are sensitive to adenoviral infection but have low hTERT promoter activity, which is consistent with our previous observation that the hTERT promoter is highly active in cancer cells but relatively quiescent in normal cells in vitro. 21, 29 FACS analysis and XTT assay showed that treatment using Ad/gTRAIL, Ad/gTRAIL plus Ad/GT-Bax, and Ad/hTERT-GV16 plus Ad/GT-Bax all Gene Therapy resulted in only a background level of cell killing in normal ovarian epithelial cells (Figure 3 ). In comparison, substantial apoptosis was induced when the cells were treated using Ad/PGK-GV16 plus Ad/GT-Bax, suggesting that the normal ovarian epithelial cells are sensitive to Bax overexpression. These results were also consistent with our previous observation that normal cells are susceptible to Bax gene overexpression and that the hTERT promoter can be used to prevent transgene expression and its related toxicity in normal cells. 21 
Suppression of intraperitoneal tumor growth and ascite formation in vivo
We next tested the effect of combined therapy in vivo in an abdominally spread tumor model derived from SKOV3ip cells. Specifically, 1 × 10 6 SKOV3ip cells were inoculated into nude mice intraperitoneally. Four days after cell inoculation, the mice were grouped randomly (15 mice per group), and intraperitoneal administration of vectors at a total dose of 6 × 10 10 viral particles (vp)/mouse/treatment was initiated. When two vectors were used, the total dose remained the same while the ratio of the two vectors was set at 1:1. Animals that received PBS were used as mock-treatment controls. At 4 weeks after cell inoculation, five mice in each group were killed, and the volume of their ascites and largest tumor nodule in their abdominal cavity were measured. In addition, the mice body weight was determined before treatment was started and 4 weeks after tumor-cell inoculation. No differences in the volume of ascites, volume of the largest tumor nodule in the abdominal cavity, or body weight were found in the animals that received PBS or control vector (Figure 4a) . However, when compared with the pretreatment amount, the mice's body weight was higher in all of the groups 4 weeks after tumor-cell inoculation. This increase in body weight may have reflected the formation of ascites in these animals, also the increase was less prominent in animals that received Ad/gTRAIL, Ad/gTRAIL plus Ad/GT-Bax or Ad/hTERT-GV16 plus Ad/GT-Bax. In these three groups, the volume of both ascites and largest tumor nodules in the abdominal cavity was significantly reduced when compared with that in the animals that received PBS or control vector (P Ͻ 0.05), suggesting that antitumor activities were elicited by these treatments. Additionally, the volume of the largest tumor nodules in animals that received Ad/gTRAIL plus Ad/GT-Bax was significantly lower than that in animals that received Ad/gTRAIL or Ad/hTERT-GV16 plus Ad/GT-Bax (P Ͻ 0.05). However, the number of the tumor nodules in the abdominal cavity was not countable in all of the groups. There were no tumor-free mice in any of the groups when the mice were killed.
The remaining 10 mice in each group were monitored for survival. The results showed that treatments using Ad/gTRAIL or Ad/hTERT-GV16 plus Ad/GT-Bax significantly improved the survival duration in animals that received it when compared with that in animals that received PBS or the control vector (P Ͻ 0.05). Furthermore, combined TRAIL and Bax treatment prolonged survival significantly when compared with treatment using either gene alone (P Ͻ 0.05) (Figure 4b ). The mean survival durations in mice that received PBS, the control vector, the TRAIL gene, the Bax gene, and both the TRAIL and Bax genes was 35, 37, 49, 48 and 68 days, respectively. Thus, significantly prolonged survival can be achieved using combined TRAIL and Bax gene therapy without an increase in vector doses.
Toxicity and transgene expression after intraperitoneal vector administration
We previously showed that the hTERT promoter is silent in murine liver, but active in murine tumor cells. 21, 29 Transgene expression in murine liver was not detected after systemic administration of an adenovirus expressing a transgene from the hTERT promoter in that study. However, the level of transgene expression after intraperitoneal vector administration remained unknown. Therefore, to test transgene expression from the hTERT promoter after intraperitoneal administration in the present study, we gave mice bearing abdominal tumors derived from SKOV3ip cells an intraperitoneal injection of Ad/hTERT-LacZ or a control vector at a single dose of 1 × 10 11 vp/mouse. We killed the animals 2 days after injection and collected their liver, spleen, intestine, kidney, pancreas, lung, ovary and peritoneum for frozen sectioning to check the level of in vivo gene expression using X-gal staining. We detected expression of bacterial ␤-galactosidase only in abdominal tumors, not in the col-
Figure 3 Transgene expression and apoptosis induction in normal human ovarian surface epithelial cells (NHOE). (a) GFP or GFP/TRAIL expression (upper panel) and apoptosis (low panel) 48 h after treatment as indicated above each panel. Number within each panel, percentage of GFP-positive cells (upper panel) and apoptotic sub-G1cells (low panel). (b) Cell viability was determined within 1 week after treatments. Cells treated using PBS were used as mock control, and their viability was set as 1.0. Values are mean ± s.d. for quadruplicate assays. ᭜, PBS; ᮀ, Ad/gTRAIL;̆, Ad/gTRAIL plus Ad/GT-Bax; , Ad/hTERT-GV16 plus Ad/GT-Bax, and ×, Ad/CMV-GFP plus Ad/GT-Bax; ᭛, Ad/PGK-GV16 plus Ad/GT-Bax. Only the treatment using Ad/PGK-GV16 plus Ad/GT-Bax elicited significant cell killing in normal cells.
lected organs or in the serosa or peritoneal cavity ( Figure  5a ). In comparison, we did not detect bacterial ␤-galactosidase expression in normal tissue, as well as in tumors after treatment using a control vector. These results confirmed the targeted gene expression using the hTERT promoter after intraperitoneal vector administration.
We also tested the toxicity of both intraperitoneal administration of the GFP/TRAIL-and Bax-expressing vectors and the combined therapy regimen described above. For this testing, serum samples were collected before treatment started and both 1 and 14 days after treatment ended. Analysis of the serum alanine transaminase (ALT) and aspartate transaminase (AST) level showed that they were both in the normal range in all of the treatment groups and at all of the time-points tested (Figure 5b) . We also examined the histopathological changes in liver, spleen, intestine, lung, kidney, ovary, pancreas and heart after these organs were collected. No obvious lesions were found in any of the organs in either treatment group. Taken together, these results suggest that intraperitoneal administration of the GFP/TRAIL and Bax genes separately or combined resulted in minimal toxicity when transgene expressions was controlled by the hTERT promoter.
Discussion
Abdominal dissemination is a common finding in cases of advanced gastrointestinal and ovarian cancer and poses formidable difficulty in clinical practice. Unfortunately, approximately 75% to 80% of patients having newly diagnosed ovarian cancer have peritoneal carciGene Therapy nomatosis. 30 Surgical debulking and chemotherapy are the main methods of dealing with this condition, but the 5-year survival rate is less than 20%. Thus, research efforts are now focused on combined multimodality treatment in an attempt to deal with this type of terminal disease. For example, gene therapy, used as either primary therapy or adjuvant therapy in combination with conventional therapy, may improve treatment. The attraction of gene therapy is that by inducing local, intratumoral expression of the desired therapeutic proteins, it may produce a constant therapeutic effect at the cancer site while reducing systemic toxicity. This approach would greatly increase the number of proteins that may be used in cancer treatment, as it would allow use of many proteins that otherwise would not be tolerated by the patient.
Treatment of ovarian cancers using the Bax gene was recently reported by others. 23, [31] [32] [33] The results of these studies showed that the antitumor activity of the Bax gene could be enhanced further when combined with that chemotherapy or radiation therapy. Also, although abdominally disseminated cancers occur over a large surface area, they are confined to a single compartment, thus, local-regional gene delivery is feasible for treatment of them. In the present study, we evaluated the therapeutic and toxic effects of the GFP/TRAIL and Bax genes both separately and combined in the treatment of abdominally spread tumors derived from the SKOV3ip cell line that is resistant to tumor necrosis factor and to several cytotoxic drugs, including diphtheria toxin, cisplatin and adriamycin. Our results showed that treatment using either the Bax or TRAIL gene driven by the hTERT promoter alone significantly suppressed tumor growth and ascites formation and prolonged animal survival. Moreover, combined TRAIL and Bax therapy further prolonged survival significantly when compared with both TRAIL and Bax therapy alone. Neither of these therapies had any detectable toxicity.
Our results also showed that combined TRAIL and Bax therapy is most effective in cells that are modestly sensitive to these genes. Also, increase in the cell-killing effect without dose escalation can be achieved using combined therapy when the cells are highly sensitive to one gene, but modestly sensitive to the other. However, if a cell line is highly resistant to one of the genes, combined therapy may not provide an advantage. In addition, the underlying mechanisms of susceptibility to the TRAIL gene, but resistance to the Bax gene observed in the DOV13 cells were not clear. However, one of our recent studies showed that a defect in the downstream caspase-3 is not sufficient to block Bax-mediated cell death. 34 It is possible that a substantial number of antibodies could be present in ascites in patients having ovarian cancer that negate adenovirus-mediated gene transferral. 38 However, promising technology used for protecting adenoviral vectors from neutralizing antibodies was recently reported by several groups. For example, modification of adenoviral vectors with polyethylene glycol [35] [36] [37] [38] and formulation of an adenoviral vector in a collagenbased matrix 39 have been reported to render gene transferral more effective in animals having anti-adenovirus immunity. Thus, with the progress made in gene therapy and other biomedical fields, treatment of disseminated abdominal cancers will become more effective and realistic.
Materials and methods
Cell lines
The human ovarian cancer cells SKOV3ip (kindly provided by Dr Mien-Chie Hung in our institution) and DOV13, and human lung cancer cell lines H1299 were grown in DMEM or RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, antibiotics and glutamine. Normal human ovarian surface epithelial cells 40 were grown in medium 199/MCDB-105, supplemented with 15% heat-inactivated fetal bovine serum, antibiotics, glutamine and epidermal growth factor (20 ng/ml).
Adenoviruses
The adenoviral vectors Ad/hTERT-LacZ, Ad/hTERT-GV16, Ad/CMV-LacZ, Ad/PGK-GV16, Ad/CMV-GFP and Ad/GT-Bax were constructed as described previously. 21, 27, 28 Ad/gTRAIL, a bicistronic adenoviral vector that expresses the GFP/TRAIL fusion protein, 24 from hTERT promoter 21 via the GAL4 gene regulatory system 27, 41 was recently constructed in our laboratory. Briefly, this vector contains two expression cassettes: one for GFP/TRAIL, whose gene is driven by a synthetic, minimal promoter composed of five sets of GAL4 binding sites and a TATAA sequence (GT promoter), the other for GAL4/VP16, a transactivator whose gene is driven by the hTERT promoter. Both cassettes were inserted into the adenoviral E1 region in a right-to-left sequence, as a GT-GFP/TRAIL-simian virus 40 polyadenylation signal-hTERT-GV16-bovine growth hormone polyadenylation signal (detailed information on plasmid cloning and adenoviral vector construction is available upon request). The GAL4 gene regulatory components are included in Ad/gTRAIL because one of our recent studies showed that the yeast GAL4 gene regulatory system can augment transgene expression from a tumor-specific promoter without compromising promoter-specificity. 41 Additionally, the expansion, purification, titration, and quality analysis of all of the vectors used were performed at the vector core facility in our institution as described previously. 20, 21 All viral preparations were found to be free of the E1+ adenovirus using PCR assay 20, 29 and endotoxins using a Limulus amebocyte lysate endotoxin detection kit (BioWhittaker, Walkersville, MD, USA). The titer determined according to the absorbancy of the dissociated virus at A260 nm (one A260 nm unit = 10 12 viral particles/ml) was used in this study, while titers determined using plaque assay were used as additive information. Particles:plaque ratios were usually between 30:1 and 100:1.
In vitro vector administration
The optimal MOI was determined by infecting each cell line with Ad/CMV-LacZ and assessing the expression of ␤-galactosidase via 5-bromo-4-chloro-3-indolyl-␤-D-galactoside (X-gal) staining. MOIs that resulted in more than 80% of cells being stained blue were used in this experiment. These MOIs were 1000 particles for H1299, normal ovarian surface epithelial cells (NHOE); 2000 particles for DOV13 cell; and 6000 particles for the SKOV-3ip cell. When two vectors were used, the total MOI remained unchanged, while the ratio was set to 1:1.
Biochemical and flow cytometric assays
Fluorescence-activated cell sorting (FACS) was performed to determine the level of in vitro GFP/TRAIL expression and number of apoptotic cells. 20, 24 In brief, 1 × 10 6 cells were plated in a 100-mm dish and given different type of treatment on the next day. Both adherent and floating cells were harvested 48 and 72 h after treatment and then separated into two groups, one group was analyzed for the GFP expression, while the other was washed with PBS and fixed in 70% ethanol at least overnight. The cells were then stained with propidium iodide for the analysis of DNA content, the apoptotic cells were quantified using flow cytometry in the Flow Cytometry Core Laboratory at our institution. In addition, Western blot analysis was performed as described previously using the following primary antibodies: anti-PARP (4C10-5; PharMingen, San Diego, CA, USA), anti-Bax (6A7; PharMingen), anti-caspase-3 (CPP32; PharMingen); anti-caspase-8 (3-1-9; PharMingen); and anti-actin (AC-15; Sigma). Cell viability was determined via XTT assay using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. 20, 24 Each experiment was performed in quadruplicate and repeated at least twice.
Mouse experiments
Animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH publication number 85-23) and institutional guidelines of the University of Texas MD Anderson CanGene Therapy cer Center. SKOV3ip cells in log-phase growth were trypsinized and washed with PBS, viable cells were counted. Next, 1 × 10 6 cells in 0.5 ml of PBS were inoculated intraperitoneally into nude mice (4-6 weeks old; 20-25 g; Charles River Laboratories, Wilmington, MA, USA). Four days after cell inoculation, the mice were divided randomly into five groups and given treatment using various vectors. The treatment repeated three times every 4 days. Unless otherwise described, all of the experiments included PBS as a mock control and Ad/hTERT-LacZ as a vector control. When two vectors were used, the total vector amount remained the same as that in single vector group, while the ratio of the two vectors was 1:1. Measurement of tumor volume, assessment of histopathological changes in the liver, spleen, intestine, lung, kidney, ovary, pancreas and heart; and serum liver enzyme ALT and AST assays were performed as described previously. 20, 29, 24 In addition, toxicity after adenoviral vector delivery was monitored. After the mice were killed, various organs were harvested and fixed in 3.8% formalin in PBS. These organs were then sectioned, stained with hematoxylin and eosin, and examined histopathologically. Also, blood samples were collected from the tail vein on days 4, 14 and 28 to monitor liver damage, specifically, the serum level of AST and ALT in each group.
In vivo transgene expression assay
On day 26 after cell inoculation, animals were given an intraperitoneal injection of Ad/hTERT-LacZ or a control vector at a dose of 1 × 10 11 vp/mouse. These animals were killed 2 days after treatment and their liver, spleen, intestine, kidney, pancreas, lung, and ovary were collected for frozen sectioning to test LacZ gene expression as described previously. 21 
Statistical analysis
Statistical differences among the treatment groups were assessed by ANOVA using the Statistica software program (StatSoft, Tulsa, OK, USA). A value P Ͻ 0.05 was considered significant. Additionally, the survival data were summarized and plotted using the Kaplan-Meier method, and the survival curves were compared using the log-rank test.
